Oral Microbiota Therapeutic Reduces CDI Recurrence in High-Risk Patients
Researchers investigated the efficacy of an oral microbiota therapeutic against recurrent Clostridioides difficile infection across high-risk subgroups.
Researchers investigated the efficacy of an oral microbiota therapeutic against recurrent Clostridioides difficile infection across high-risk subgroups.
Researchers assessed the bacterial microbiome of the facial skin and oropharynx among individuals who wore fresh surgical masks daily vs reused masks for 1 week.
Researchers analyzed functional and compositional changes in gut microbiota among individuals with and without psychosis or schizophrenia.
Researchers examined the relationship between long-term antibiotic exposure and the risk for lung cancer.
Researchers investigated whether gut microbiota have a causal relationship with irritable bowel syndrome.
Researchers sought to determine the role of the gut microbiome in diet modifications and cardiometabolic health in prediabetes.
Researchers sought to determine whether the microbiome plays a role in the pathogenesis of diverticulosis or diverticular disease.
Researchers evaluated the safety of SER-109 and its effect on CDI recurrence among adult outpatients.
Researchers investigated whether a human milk diet vs bovine milk diet would affect the gut microbiome of preterm infants.
Investigators conducted a systematic review and meta-analysis to assess the safety and efficacy of fecal microbiota transplantation for C difficile infection in pediatric patients.